Therapy for chronic hepatitis B with tenofovir disoproxil fumarate (TDF) and lamivudine (3TC) or emtricitabine (FTC) is currently recommended for HIV–HBV coinfection. However, there is limited randomized data on the efficacy of combined therapy with TDF and FTC, especially in antiretroviral (ARV)-naive patients.
Methods
This was a prospective randomized clinical trial comparing the efficacy of HBV monotherapy with FTC versus TDF/FTC combination therapy in ARV-naive HIV– HBV coinfection. HIV–HBV-coinfected patients initiating ARV were randomized to either FTC/zidovudine/efavirenz (EFV; n=6) or TDF/FTC/EFV (n=10). The primary end point was the time-weighted area under the curve (TWAUC) of HBV DNA at 48 weeks.
Results
The median baseline CD4+ T-cell count was 64 cells/μl (interquartile range [IQR] 36–172), plasma HIV type-1 RNA was 4.90 log10 copies/ml (IQR 4.58–5.44) and plasma HBV DNA was 8.76 log10 copies/ml (IQR 8.45–8.82). A total of 11/16 (69%) patients were hepatitis B e antigen (HBeAg)-positive. The median TWAUC decrease in HBV DNA was -5.32 log10 copies/ml in the TDF/FTC group compared with -3.25 log10 copies/ml in the FTC group (P=0.03). At week 48, 90% of the TDF/FTC group and 33% of the FTC group had plasma HBV DNA<170 copies/ ml (P=0.036, intention-to-treat analysis). HBeAg loss was observed in 4/11 (36%) HBeAg-positive patients. Hepatic fares were observed in 3/16 (19%) of patients.
Conclusions
TDF/FTC combination therapy resulted in a significantly greater decrease in HBV DNA than FTC monotherapy, with a greater proportion of patients with undetectable HBV DNA at week 48. Our study supports the current recommendation of ARV containing TDF/FTC as the treatment of choice for patients with HIV–HBV coinfection.
References
1.
ThioC.L., SeabergE.C., SkolaskyR.Jr.. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS).Lancet2002; 360: 1921–1926.
2.
Salmon-CeronD., LewdenC., MorlatP.Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol.J Hepatol2005; 42: 799–805.
GishR.G., TrinhH., LeungN.Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study.J Hepatol2005; 43: 60–66.
5.
MatthewsG.V., AvihingsanonA., LewinS.R.A randomized trial of combination hepatitis B therapy in HIV/ HBV coinfected antiretroviral naive individuals in Thailand.Hepatology2008; 48: 1062–1069.
6.
ZhuY., CurtisM., QiX.Anti-hepatitis B virus activity in vitro of combinations of tenofovir with nucleoside/ nucleotide analogues.Antivir Chem Chemother2009; 19: 165–176.
7.
FengJ.Y., LyJ.K., MyrickF.The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study.Retrovirology2009; 6: 44.
8.
MenneS., ButlerS.D., GeorgeA.L.Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.Antimicrob Agents Chemother2008; 52: 3617–3632.
9.
GishR.G., LeungN.W., WrightT.L.Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection.Antimicrob Agents Chemother2002; 46: 1734–1740.
10.
BenhamouY., FleuryH., TrimouletP.Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients.Hepatology2006; 43: 548–555.
11.
AudsleyJ., ArrifinN., YuenL.K.Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations.HIV Med2009; 10: 229–235.
12.
SheldonJ., CaminoN., RodesB.Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir.Antivir Ther2005; 10: 727–734.
13.
van BommelF., de ManR.A., WedemeyerH.Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues.Hepatology201051: 73–80.
14.
LimS.G., NgT.M., KungN.A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B.Arch Intern Med2006; 166: 49–56.
15.
MatthewsG.V., BartholomeuszA., LocarniniS.Characteristics of drug resistant HBV in an international collaborative study of HIV–HBV-infected individuals on extended lamivudine therapy.AIDS2006; 20: 863–870.
16.
YuenM.F., SablonE., HuiC.K.Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.Hepatology2001; 34: 785–791.
17.
JainM.K., ComanorL., WhiteC.Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response.J Viral Hepat2007; 14: 176–182.
18.
MarcellinP., HeathcoteE.J., ButiM.Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.N Engl J Med2008; 359: 2442–2455.
19.
ChangT.T., GishR.G., de ManR.A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.N Engl J Med2006; 354: 1001–1010.
